Log in
Enquire now
‌

US Patent 7098190 Formulations comprising antisense nucleotides to connexins

Patent 7098190 was granted and assigned to CoDa Therapeutics on August, 2006 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Current Assignee
‌
CoDa Therapeutics
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
70981900
Patent Inventor Names
Colin Richard Green0
David Laurence Becker0
Date of Patent
August 29, 2006
0
Patent Application Number
098903630
Date Filed
January 27, 2000
0
Patent Citations Received
‌
US Patent 11926828 Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1
0
‌
US Patent 12128086 Formulations and methods of use for alpha connexin c-terminal (ACT) peptides
0
Patent Primary Examiner
‌
Sean McGarry
0
Patent abstract

A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 7098190 Formulations comprising antisense nucleotides to connexins

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.